1999
Cellular pharmacology of polynuclear platinum anti-cancer agents
Roberts J, Peroutka J, Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. Journal Of Inorganic Biochemistry 1999, 77: 51-57. PMID: 10626354, DOI: 10.1016/s0162-0134(99)00147-6.Peer-Reviewed Original ResearchConceptsCisplatin-resistant cell linesCell linesCross-linking adductsWild-type cell linesDNA repair mechanismsL1210 murine leukemia cell lineCellular pharmacologyType cell linesGenomic accessMurine leukemia cell lineWild typeCytotoxic effectsLeukemia cell linesRepair mechanismsDNA interstrandAnti-cancer agentsDiminished accumulationDinuclear platinum complexesTrinuclear platinum complexBBR3464Enhanced activityPotential anticancer agentsPotent cytotoxic agentComplexesVivo activity
1996
Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration
Bear H, McFadden A, Kostuchenko P, Lipshy K, Hamad G, Turner A, Roberts J, Carr M, Carr S, Grant S. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Anti-Cancer Drugs 1996, 7: 299-306. PMID: 8792004, DOI: 10.1097/00001813-199605000-00010.Peer-Reviewed Original ResearchConceptsBryostatin 1Normal murine spleen cellsT-cell activation marker CD69PKC activityActivation marker CD69Single bolus injectionEarly lymphocyte activationSingle intravenous administrationAnti-tumor effectsNormal host tissuesCell surface phenotypeProtein kinase CMurine spleen cellsPlasma levels resultsRegulate protein kinase CAnti-cancer agentsControl miceMarked splenomegalyBolus injectionIntravenous administrationC57BI/6 miceSpleen cellsSplenocyte proliferationSplenic lymphocytesSurface phenotype